{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T01:26:17Z","timestamp":1792113977470,"version":"4.4.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T00:00:00Z","timestamp":1756252800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T00:00:00Z","timestamp":1756252800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-16848-y","type":"journal-article","created":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T15:51:19Z","timestamp":1756309879000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Distinct safety profiles of albumin-bound nab-paclitaxel and paclitaxel in pancreatic cancer focusing on hematologic and hepatobiliary risks"],"prefix":"10.1038","volume":"15","author":[{"given":"Nan","family":"Qin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongliu","family":"Bian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingtao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,27]]},"reference":[{"key":"16848_CR1","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/S0140-6736(25)00261-2","volume":"405","author":"TF Stoop","year":"2025","unstructured":"Stoop, T. F. et al. Pancreatic cancer. Lancet 405, 1182\u20131202. https:\/\/doi.org\/10.1016\/S0140-6736(25)00261-2 (2025).","journal-title":"Lancet"},{"key":"16848_CR2","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41575-021-00457-x","volume":"18","author":"AP Klein","year":"2021","unstructured":"Klein, A. P. Pancreatic cancer epidemiology: Understanding the role of lifestyle and inherited risk factors. Nat. Rev. Gastroenterol. Hepatol. 18, 493\u2013502. https:\/\/doi.org\/10.1038\/s41575-021-00457-x (2021).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"16848_CR3","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.hoc.2022.07.006","volume":"36","author":"M Rehman","year":"2022","unstructured":"Rehman, M., Khaled, A. & Noel, M. Cytotoxic chemotherapy in advanced pancreatic cancer. Hematol. Oncol. Clin. North. Am. 36, 1011\u20131018. https:\/\/doi.org\/10.1016\/j.hoc.2022.07.006 (2022).","journal-title":"Hematol. Oncol. Clin. North. Am."},{"key":"16848_CR4","doi-asserted-by":"publisher","first-page":"9587","DOI":"10.3390\/curroncol30110694","volume":"30","author":"I Garajov\u00e1","year":"2023","unstructured":"Garajov\u00e1, I., Peroni, M., Gelsomino, F. & Leonardi, F. A simple overview of pancreatic cancer treatment for clinical oncologists. Curr. Oncol. 30, 9587\u20139601. https:\/\/doi.org\/10.3390\/curroncol30110694 (2023).","journal-title":"Curr. Oncol."},{"key":"16848_CR5","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1517\/17425247.2013.752354","volume":"10","author":"Z Zhang","year":"2013","unstructured":"Zhang, Z., Mei, L. & Feng, S. S. Paclitaxel drug delivery systems. Expert Opin. Drug Deliv. 10, 325\u2013340. https:\/\/doi.org\/10.1517\/17425247.2013.752354 (2013).","journal-title":"Expert Opin. Drug Deliv."},{"key":"16848_CR6","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1021\/acs.molpharmaceut.1c00046","volume":"18","author":"A Spada","year":"2021","unstructured":"Spada, A., Emami, J., Tuszynski, J. A. & Lavasanifar, A. The uniqueness of albumin as a carrier in nanodrug delivery. Mol. Pharm. 18, 1862\u20131894. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.1c00046 (2021).","journal-title":"Mol. Pharm."},{"key":"16848_CR7","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","volume":"13","author":"KJ Rothman","year":"2004","unstructured":"Rothman, K. J., Lanes, S. & Sacks, S. T. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol. Drug Saf. 13, 519\u2013523. https:\/\/doi.org\/10.1002\/pds.1001 (2004).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"16848_CR8","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","volume":"10","author":"SJ Evans","year":"2001","unstructured":"Evans, S. J., Waller, P. C. & Davis, S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol. Drug Saf. 10, 483\u2013486. https:\/\/doi.org\/10.1002\/pds.677 (2001).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"16848_CR9","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1080\/00031305.1999.10474456","volume":"53","author":"Dumouchel & William","year":"1999","unstructured":"Dumouchel & William. Bayesian data mining in large frequency tables, with an application to the fda spontaneous reporting system. Am. Stat. 53, 177\u2013190 (1999).","journal-title":"Am. Stat."},{"key":"16848_CR10","unstructured":"G., B. R: A Language and Environment for Statistical Computing. (2013)."},{"key":"16848_CR11","unstructured":"Klaus & Galensa. ggplot2: Elegant graphics for data analysis (2nd ed.). Computing Reviews (2017)."},{"key":"16848_CR12","doi-asserted-by":"publisher","first-page":"3527","DOI":"10.7150\/THNO.49421","volume":"11","author":"C Qizhen","year":"2021","unstructured":"Qizhen, C., Qian, H., Wang, Y. A. & Chun, L. Abraxane-induced bone marrow CD11b+ myeloid cell depletion in tumor-bearing mice is visualized by \u03bcPET-CT with 64Cu-labeled anti-CD11b and prevented by anti-CSF-1. Theranostics 11, 3527\u20133539. https:\/\/doi.org\/10.7150\/THNO.49421 (2021).","journal-title":"Theranostics"},{"key":"16848_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2023.10.022","author":"A Annika","year":"2023","unstructured":"Annika, A. et al. Challenges of nanoparticle albumin bound (nab\u2122) technology: Comparative study of Abraxane\u00ae with a newly developed albumin-stabilized itraconazole nanosuspension. Eur. J. Pharm. Biopharm. https:\/\/doi.org\/10.1016\/j.ejpb.2023.10.022 (2023).","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"16848_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrep.2024.101713","author":"K Yusuke","year":"2024","unstructured":"Yusuke, K., Tomoyuki, S., Hikaru, Y., Hideo, O. & Ken Ichi, O. Preparation of stable and monodisperse paclitaxel-loaded bovine serum albumin nanoparticles via intermolecular disulfide crosslinking. Biochem. Biophys. Rep. https:\/\/doi.org\/10.1016\/j.bbrep.2024.101713 (2024).","journal-title":"Biochem. Biophys. Rep."},{"key":"16848_CR15","doi-asserted-by":"publisher","first-page":"1703670","DOI":"10.1002\/SMLL.201703670","volume":"14","author":"P Joon-Young","year":"2018","unstructured":"Joon-Young, P. et al. A comparative in vivo study of albumin-coated paclitaxel nanocrystals and abraxane. Small 14, 1703670. https:\/\/doi.org\/10.1002\/SMLL.201703670 (2018).","journal-title":"Small"},{"key":"16848_CR16","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1080\/10717544.2022.2046892","volume":"29","author":"C Yuxin","year":"2022","unstructured":"Yuxin, C. et al. Reassembling of albumin-bound paclitaxel mitigates myelosuppression and improves its antitumoral efficacy via neutrophil-mediated targeting drug delivery. Drug Deliv. 29, 728\u2013742. https:\/\/doi.org\/10.1080\/10717544.2022.2046892 (2022).","journal-title":"Drug Deliv."},{"key":"16848_CR17","doi-asserted-by":"publisher","first-page":"19736","DOI":"10.1021\/ACSAMI.1C03065","volume":"13","author":"H Maichi","year":"2021","unstructured":"Maichi, H. et al. Evidence for delivery of abraxane via a denatured-albumin transport system. ACS Appl. Mater. Interfac. 13, 19736\u201319744. https:\/\/doi.org\/10.1021\/ACSAMI.1C03065 (2021).","journal-title":"ACS Appl. Mater. Interfac."},{"key":"16848_CR18","doi-asserted-by":"publisher","unstructured":"Neil, P. D. Nanoparticle Albumin-Bound Anticancer Agents. 335\u2013354 https:\/\/doi.org\/10.1007\/978-3-319-16241-6_10 (2015).","DOI":"10.1007\/978-3-319-16241-6_10"},{"key":"16848_CR19","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/S12016-014-8416-0","volume":"49","author":"P Matthieu","year":"2015","unstructured":"Matthieu, P. & Mariana, C. Re-visiting hypersensitivity reactions to taxanes: A comprehensive review. Clin. Rev. Allergy Immunol. 49, 177\u2013191. https:\/\/doi.org\/10.1007\/S12016-014-8416-0 (2015).","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"16848_CR20","doi-asserted-by":"publisher","first-page":"4988","DOI":"10.3390\/IJMS20204988","volume":"20","author":"P Chen","year":"2019","unstructured":"Chen, P. et al. The involvement of the RhoA\/ROCK signaling pathway in hypersensitivity reactions induced by paclitaxel injection. Int. J. Mol. Sci. 20, 4988. https:\/\/doi.org\/10.3390\/IJMS20204988 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"16848_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-04964-w","author":"B Laura","year":"2022","unstructured":"Laura, B. et al. Paclitaxel binds and activates C5aR1: A new potential therapeutic target for the prevention of chemotherapy-induced peripheral neuropathy and hypersensitivity reactions. Cell Death Dis. https:\/\/doi.org\/10.1038\/s41419-022-04964-w (2022).","journal-title":"Cell Death Dis."},{"key":"16848_CR22","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1177\/10781552221080415","volume":"29","author":"G-D Sandra Nora","year":"2022","unstructured":"Sandra Nora, G.-D., Alejandra, C.-P., Alejandra, M.-W., Oscar, V.-G. & Rosalaura Virginia, V.-G. Atopy, allergen sensitization and development of hypersensitivity reactions to paclitaxel. J. Oncol. Pharm. Pract. 29, 810\u2013817. https:\/\/doi.org\/10.1177\/10781552221080415 (2022).","journal-title":"J. Oncol. Pharm. Pract."},{"key":"16848_CR23","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/bs.acr.2022.02.007","volume":"155","author":"IA Hamid","year":"2022","unstructured":"Hamid, I. A., Karan, H. M., Donald, K. J. & Stanley, M. C. Chemotherapy induced gastrointestinal toxicities. 155, 131\u2013166. https:\/\/doi.org\/10.1016\/bs.acr.2022.02.007 (2022).","journal-title":"Chemotherapy induced gastrointestinal toxicities."},{"key":"16848_CR24","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1159\/000096150","volume":"29","author":"H de Dick","year":"2006","unstructured":"de Dick, H. & van den Michiel, B. Colonic perforation secondary to taxol therapy: An unusual presentation. Onkologie 29, 541\u2013542. https:\/\/doi.org\/10.1159\/000096150 (2006).","journal-title":"Onkologie"},{"key":"16848_CR25","doi-asserted-by":"publisher","first-page":"414","DOI":"10.3389\/FPHAR.2016.00414","volume":"7","author":"MM Rachel","year":"2016","unstructured":"Rachel, M. M., Vanesa, S., Raquel, A., Joel, C. B. & Kulmira, N. Chemotherapy-induced constipation and diarrhea: pathophysiology, current and emerging treatments. Front. Pharmacol. 7, 414\u2013414. https:\/\/doi.org\/10.3389\/FPHAR.2016.00414 (2016).","journal-title":"Front. Pharmacol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-16848-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-16848-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-16848-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T04:51:05Z","timestamp":1757479865000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-16848-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,27]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["16848"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-16848-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,27]]},"assertion":[{"value":"22 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All authors have contributed to, read, and approved this submitted manuscript in its current form.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"31602"}}